Frontiers editorial spotlights inflammaging in animal aging

CURRENT FULL VERSION: A new editorial in Frontiers in Veterinary Science argues that “inflammaging” may be one of the most important biologic threads connecting aging to chronic disease in animals. Published May 8, 2026, the article by Toshiro Arai frames chronic, low-grade inflammation, cellular senescence, immunosenescence, and organ dysfunction as overlapping processes that help drive age-related disease across species. (frontiersin.org)

The editorial serves as the introduction to the journal’s second “Unraveling inflammaging” research topic, a collection that brings together studies and reviews on aging in companion animals. According to the topic page, the volume includes work on species- and breed-associated periodontal disease risk in dogs and cats, nutraceutical supplementation in senior dogs, age-related obesity and inflammaging in cats, and resveratrol supplementation in healthy and obese cats. In other words, the field is moving beyond theory and into specific disease areas and intervention strategies. (frontiersin.org)

Arai’s editorial lays out the core mechanism: aging is associated with chronic systemic inflammation, and senescent cells contribute to that state through the senescence-associated secretory phenotype, or SASP. The editorial notes that SASP includes inflammatory cytokines, chemokines, growth factors, matrix metalloproteases, lipids, nucleotides, extracellular vesicles, and other soluble mediators that can amplify tissue dysfunction over time. It also points to blood biomarkers such as CRP, IL-6, IL-8, TNF-α, and serum amyloid A as part of the inflammaging conversation, while emphasizing prevention-oriented approaches such as nutrition, early diagnosis, and regenerative strategies. (frontiersin.org)

That framework aligns with a broader veterinary literature review published in the Journal of Veterinary Internal Medicine in 2025. That review concluded that dogs and cats appear to share some of the same broad inflammaging patterns seen in humans and laboratory species, including age-associated increases in some pro-inflammatory mediators and links to conditions such as cardiac disease, chronic kidney disease, neoplasia, frailty, and degenerative disorders. At the same time, the authors stressed that the veterinary evidence base is still sparse, especially for cats, and that some commonly discussed biomarkers have not yet shown consistent age-related associations in dogs. (academic.oup.com)

Related reporting and commentary suggest the concept is already influencing adjacent areas of practice. AVMA’s Veterinary Vertex recently highlighted cellular senescence in equine osteoarthritis research, including discussion with Dr. Lynn Pezzanite about how SASP-related biology may worsen joint damage over time and why horses can be a useful One Health model for osteoarthritis and aging research. The featured AJVR study used single-cell RNA sequencing to compare synovial fluid cells from affected joints with peripheral blood mononuclear cells, helping separate immune and cellular heterogeneity that bulk methods can miss. One of the key findings was a compartment-specific split: senescence-associated pathways appeared upregulated in synovial cells but downregulated in peripheral blood, suggesting that diseased joints may develop a more intense and specialized senescent phenotype than blood testing alone would indicate. The discussion also highlighted recurring immune-cell signals, including dendritic cells and gamma delta T cells, across both chronic naturally occurring osteoarthritis and early post-traumatic osteoarthritis work. Clinically, that points toward both the promise and the caution of senescence-targeted therapies, with local intra-articular delivery emerging as a practical strategy but with unresolved questions around equine-specific dosing, safety, and how well senescence burden tracks with pain and treatment response. dvm360 has also tied inflammaging to oral disease and broader healthy-aging strategies in dogs, reflecting growing industry interest in aging as a modifiable clinical risk factor rather than an unavoidable background condition. (veterinaryvertex.buzzsprout.com)

Why it matters: For veterinarians, this editorial doesn’t change standards of care on its own, but it does reinforce where the science is heading. If inflammaging proves to be a workable clinical framework, it could reshape senior care around earlier screening, weight and nutrition management, periodontal prevention, mobility monitoring, and eventually biomarker-guided intervention. The equine osteoarthritis example adds an important nuance: inflammaging and senescence may be highly tissue-specific, which means blood-based markers could miss clinically relevant local disease biology and local treatment approaches may sometimes make more sense than systemic ones. It also supports a more integrated conversation with pet parents: age-related disease may not be a series of isolated problems, but a network of inflammatory and metabolic changes that starts well before obvious clinical decline. That said, the gap between promising mechanisms and validated tools in practice remains substantial. (frontiersin.org; veterinaryvertex.buzzsprout.com)

What to watch: The next step is whether this research topic yields biomarkers and interventions that are reproducible, affordable, and useful in general practice, particularly in dogs and cats. Watch for follow-on studies validating inflammatory markers, nutrition trials in senior animals, and translational work on senescence-targeted therapies that can move from concept to clinic over the next few years. In horses, key follow-ups will include studies linking senescence signatures to osteoarthritis pain and treatment response, along with practical work on intra-articular delivery, dosing, and safety. (frontiersin.org; veterinaryvertex.buzzsprout.com)